Alliance Pharma PLC Hardman Res.: Transformed International Business
May 25 2017 - 2:15AM
RNS Non-Regulatory
TIDMAPH
Alliance Pharma PLC
25 May 2017
Hardman Res.: Transformed International Business
Transformed International Business - Alliance Pharma's
buy-and-build strategy to evolve into a profitable, cash
generative, specialty pharma business is clearly bearing fruit.
Acquisition of the dermatology and woundcare products from Sinclair
Pharma was transformational, doubling the size of the company and
providing a more internationally-oriented business. The enlarged
group is also a more attractive and credible partner for
in-licensing and M&A opportunities. 2017 looks set to be an
exciting year for the group: not only is there solid underlying
growth potential in the re-focused group, but also regulatory
approval of Diclectin offers further significant growth
potential.
Please click here for the full report:
http://www.hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/25.05.17-a-transformational-year-driving-growth.pdf
To contact us: Contacts:
Hardman & Co Dr Martin Hall
35 New Broad Street mh@hardmanandco.com
London Dr Dorothea Hill
EC2M 1NH dmh@hardmanandco.com
Dr Gregoire Pave
gp@hardmanabdco.com
Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGMGZKNDZGNZM
(END) Dow Jones Newswires
May 25, 2017 02:15 ET (06:15 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024